Pulmozyme Financial Support Center: Overview for patients and Legally Authorized Persons

About Financial Support Center

Pulmozyme Financial Support Center provides you with information and guidance on financial assistance options for Pulmozyme. You can use this site to learn more about our programs, find out if you are eligible, and enroll. Plus, your eligibility and enrollment information will be stored in your account for quick and easy access.

How Financial Support Center works

To check your eligibility and enroll in a program, you need to register with us by filling out a form and creating a password. From there, you will be directed to the appropriate assistance option for you.

Program descriptions

The Pulmozyme Voucher Program provides a free, initial 30-day supply of Pulmozyme to eligible patients.

The Pulmozyme Co-pay Program works to help eligible, commercially insured patients pay as little as $30 per month for Pulmozyme. It covers any additional out-of-pocket costs for Pulmozyme, after you pay $30 for each 30-day supply, up to $10,000 per year, for most privately insured patients.

Program eligibility requirements

Patients may be eligible for the Voucher if they:
  • Have never taken Pulmozyme before
  • Have a valid prescription for Pulmozyme for an FDA-approved use
  • Live in the United States or U.S. Territories
  • Are over the age of 18, or have a Legally Authorized Person over the age of 18 to manage the Voucher
Patients may be eligible for the Co-pay Program if they:
  • Have a valid prescription for Pulmozyme for an FDA-approved use
  • Reside in the United States or U.S. Territories
  • Are over the age of 18, or have a Legally Authorized Person over the age of 18 to manage the card
  • Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
  • Are not getting help for Pulmozyme from the Genentech Patient Foundation or any independent co-pay assistance foundations
  • Are not using a state or federal healthcare plan to pay for their medication. This includes, but is not limited to, Medicare, Medicaid and TRICARE

Please see Terms and Conditions for full eligibility requirements.

How to enroll with Financial Support Center

Once you have registered with us, you will be directed to the savings program that is right for you.

Once you have enrolled in the Co-pay Program, your card information will be stored on this site under your account. You can log in at any time to view your account balance, print your card, or request that a copy be emailed to you.

The importance of creating an account

We request that you provide some personal information and create an account so that we can recognize you whenever you visit the site and provide you with the most personalized support possible. With unique login information, you will be able to access your card information or easily activate a new card, so you don't have to worry if it gets lost or expires.

GET STARTED

Important Safety Information & Indication

 

Indication and Usage

Pulmozyme (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.

In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.

Important Safety Information

Pulmozyme should not be used in patients who are allergic to any of its ingredients.

Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion, and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.

Pediatric Use

The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.

The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to <5 years (younger group) and 33 aged 5 years to <10 years (older group). The PARI BABY reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.

You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Pulmozyme Prescribing Information for additional Important Safety Information. If you have questions, please discuss them with your CF Care Team.